RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Prostate cancer (PCa) progression to androgen independence leads to treatment failure.
• Alternative therapeutic pathways beyond the androgen receptor are under investigation.
• The PI3K/AKT pathway is a known regulator of cancer cell proliferation and survival.

Purpose of the Study:

• To investigate the role of RASAL2 in prostate cancer.
• To elucidate the molecular mechanisms by which RASAL2 influences PCa growth and progression.
• To determine if RASAL2 could serve as a therapeutic target in PCa.

Main Methods:

• Analysis of RASAL2 expression in PCa tissues and matched adjacent nontumor tissues.
• In vitro studies assessing the impact of RASAL2 on cancer cell proliferation and cell cycle progression.
• In vivo studies using xenograft models to evaluate tumor growth.
• Western blot analysis to assess protein phosphorylation and expression levels, including AKT and cyclin D1.

Main Results:

• RASAL2 expression was significantly higher in PCa tissues compared to nontumor tissues.
• Elevated RASAL2 expression correlated with higher PCa tumor stage, Gleason score, and poorer prognosis.
• RASAL2 promoted cancer cell proliferation, G1 to S phase transition, and tumor growth in vivo.
• RASAL2 facilitated AKT phosphorylation, leading to increased cyclin D1 expression.
• A positive correlation was observed between RASAL2 and cyclin D1 expression in xenografts and clinical specimens.

Conclusions:

• RASAL2 functions as an oncogene in prostate cancer.
• RASAL2 promotes PCa tumorigenesis by regulating the PI3K/AKT signaling pathway and cyclin D1 expression.
• RASAL2 represents a potential therapeutic target for prostate cancer treatment.